All Stories

  1. An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study)

    Article • Canadian Journal of Kidney Health and Disease, January 2018, SAGE Publications

    Guillaume Feugère

  2. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

    Article • ClinicoEconomics and Outcomes Research, January 2017, Dove Medical Press

    Dr Lesley G Shane, Guillaume Feugère

  3. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment

    Article • Journal of Thrombosis and Thrombolysis, June 2016, Springer Science + Business Media

    Guillaume Feugère

  4. Anticoagulant use in patients with cancer associated venous thromboembolism: A retrospective cohort study

    Article • Thrombosis Research, March 2013, Elsevier

    Dr Elham Rahme, Guillaume Feugère